BFM
AGRX

Boothbay Fund Management’s Agile Therapeutics AGRX Stock Holding History

Boothbay Fund Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15
Closed -$40K – 2301
2021
Q2 		$40K Buy
+15
New +$49.5K ﹤0.01% 1775
2019
Q4 		– Sell
-18
Closed -$42K – 1050
2019
Q3 		$42K Buy
+18
New +$44.3K ﹤0.01% 729
2016
Q4 		– Sell
-7
Closed -$103K – 994
2016
Q3 		$103K Buy
+7
New +$99.9K 0.02% 635

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Boothbay Fund Management's AGRX Position: Q3 2021 in Review

Boothbay Fund Management sold out of Agile Therapeutics (AGRX) in Q3 2021, closing a stake of 15 shares — an estimated $40K sold.

Boothbay Fund Management first reported a position in AGRX in Q3 2016 and held it in 3 quarters. The position peaked at $103K in Q3 2016. 49 funds tracked by Wall St. Rank hold AGRX as of Q3 2021.

  • Boothbay Fund Management reported no remaining Agile Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Boothbay Fund Management sold 15 Agile Therapeutics shares in Q3 2021, an estimated $40K.
  • Boothbay Fund Management first reported a position in Agile Therapeutics in Q3 2016 and held it in 3 quarters.
  • Boothbay Fund Management's Agile Therapeutics position peaked at $103K in Q3 2016.
  • 49 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2021.

Based on Boothbay Fund Management's 13F filing for Q3 2021, filed 15 Nov 2021.